Daily Zinc Cuts Infection Risk in Pediatric Sickle Cell

Infection Vulnerability in Sickle Cell Anemia

Young children with sickle cell disorders face high rates of life-threatening infections. Therefore, evaluating zinc supplementation in sickle cell management offers vital clinical hope. In low-resource settings, recurrent bacteremia and respiratory illnesses drive substantial mortality. Hydroxyurea provides significant organ protection and improves clinical outcomes. However, infectious complications frequently persist despite standard preventive therapies.

ZIPS-2 Trial: Zinc Supplementation in Sickle Cell

Researchers conducted the randomized, double-blind ZIPS-2 clinical trial at Jinja Regional Referral Hospital in Uganda. Specifically, the investigators enrolled 100 children aged 1.00 to 4.99 years diagnosed with sickle cell anemia. Clinicians assigned participants to receive either 20 mg of oral zinc sulfate daily or an identical placebo for six months. Furthermore, all participants continued or initiated hydroxyurea therapy during the study period. The primary endpoint measured all-cause infection rates per 100 person-years.

Key Findings and Clinical Significance

The study recorded 80 all-cause infections in the zinc group compared to 124 infections in the placebo cohort. Consequently, daily zinc reduced infection incidence from 480.7 to 305.7 per 100 person-years. After adjusting for baseline age, sex, and hydroxyurea use, zinc achieved an adjusted incidence rate ratio of 0.62. In addition, participants tolerated the daily 20 mg dose exceptionally well. No adverse events required treatment discontinuation throughout the follow-up period.

Implications for Indian Healthcare Practice

India bears a heavy burden of sickle cell disease across tribal and central regions. Consequently, preventing childhood infections remains a top priority under the National Sickle Cell Anaemia Elimination Mission. Daily zinc represents an accessible, cost-effective adjuvant alongside hydroxyurea. However, clinicians require larger multisite confirmatory trials before establishing universal guidelines for older pediatric cohorts.

Frequently Asked Questions

Q1: What dose of zinc was evaluated in the ZIPS-2 clinical trial?

The trial evaluated daily oral zinc sulfate at a dose of 20 mg administered over six months in children under five years.

Q2: Did zinc supplementation reduce infection risk in children already receiving hydroxyurea?

Yes, zinc significantly reduced all-cause infections even after researchers adjusted for concurrent hydroxyurea therapy.

Q3: Were any significant adverse events reported with daily zinc therapy?

No, the investigators observed no serious adverse events requiring discontinuation of the study intervention.

References

1. Namazzi R et al. Daily Zinc Supplementation for Infection Prevention in Children With Sickle Cell Anemia: The ZIPS-2 Randomized Clinical Trial. JAMA. 2026 Aug 19. doi: 10.1001/jama.2026.14190. PMID: 42616536.
2. Namazzi R, Datta D, Conroy AL, et al. Zinc for infection prevention in children with sickle cell anemia: a randomized double-blind placebo-controlled trial. Blood Adv. 2023;7(17):5119-5129.
3. Gupta VL, Chaubey BS. Efficacy of zinc therapy in prevention of crisis in sickle cell anemia: a double blind, randomized controlled clinical trial. J Assoc Physicians India. 1995;43(7):467-469.